| Epicept: Good Play in Light of Recent Developments VFC submits: Epicept Corporation (EPCT) announced on Tuesday that the European Medicines Agency [EMA] considers the company's post-approval commitments for Ceplene fulfilled. Originally the agency had required Epicept to conduct an additional confirmatory Phase III trial evaluating Ceplene with low-dose interleukin-2 (IL-2) versus a comparator arm of either no treatment or IL-2 alone, but the EMA ultimately agreed with a panel put together to assess the situation and decided that such a trial was not feasible. Epicept continues to enroll patients for a separate ongoing post-approval trial with an estimated completion date of sometime in 2011. Complete Story » seekingalpha.com |
Cephalon Q2 2010 Earnings Call Transcript Cephalon (CEPH)Q2 2010 Earnings CallJuly 27, 2010 5:00 pm ETComplete Story » seekingalpha.com |
Cord Blood America Reports 12% Increase in 2010 Second Quarter Revenue (PR Newswire) Cord Blood America, Inc. , the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, announced today that revenues for the second quarter ended June 30, 2010, increased 12 percent to $951,561 compared to $813,950 in the same period in 2009. us.rd.yahoo.com |
Justices Wrestle With Vaccine Case The Supreme Court wrestled with the potential consequences of a case that asks the justices to decide whether federal law shields vaccine makers from some types of product-liability lawsuits. online.wsj.com |
Stent-Graft Study Points to Oversight Gap An unusually high percentage of the participants in a clinical trial for an aortic-aneurysm treatment known as a stent-graft, developed blood clots. online.wsj.com |